

European CLO issuance was strong in 2019, with volumes up c. 10% year-on-year. However, signals in the leveraged loan market have been mixed, with lower supply and deteriorating credit quality. Entering 2020, we expect CLO issuance to remain solid as interest rates will stay low.

European CLOs remain popular among investors, providing a high-yield alternative in a low-spread environment. Over EUR 40bn was deployed in 2019, a mixture of new deals (72%) and refinancings (28%). This was despite a clear slowdown in leveraged loan activity due to fewer corporate acquisitions and buyouts.

While we expect the asset class to stay strong in 2020, a number of risks could materialise, including deteriorating credit quality among sub-investment-grade corporates and tighter spread arbitrage.


CLO managers keep bringing new deals, with an emphasis on the alignment of interests necessary to attract investors at the lower end of the capital structure. As new managers continue to enter the market, we expect a broader mix of investors and less reliance on anchor investors.

CLOs: Increasing volumes despite tightening in spread arbitrage

Issuance volumes continued to rise in 2019, following the trend of recent years. This was driven by a strong fourth quarter, topping EUR 30bn across more than 70 deals, a 10% increase from 2018. Eight new managers entered the market, the highest level since the financial crisis.

In 2020, we expect European CLO volumes to reach the levels of over the past two years as investor demand will remain solid, with ECB monetary policy set to remain accommodative. This will support the yield-enhancing nature of CLOs relative to other asset-backed segments.

Figure 1: EUR CLO new issuance to-date



Source: Scope Ratings

Analysts

Benoit Vasseur +49 69 6677389 40 b.vasseur@scoperatings.com

Cyrus Mohadjer +49 69 6677389 59 c.mohadjer@scoperatings.com

Media

André Fischer a.fischer@scopegroup.com

Related Research

European CLO Outlook 2019 – December 2018

Tight spread arbitrage leaves investors and European CLO managers with tougher decisions – May 2019

Scope Ratings GmbH

Neue Mainzer Straße 66-68 D-60311 Frankfurt am Main

Phone +49 69 66 77 389 0

Headquarters

Lennéstraße 5 10785 Berlin

Phone +49 30 27891 0 Fax +49 30 27891 100

info@scoperatings.com www.scoperatings.com





Bloomberg: SCOP


8 January 2020 1/5



Higher liability spreads in 2019

In 2019, the two ends of the capital structure saw spread behaviour diverge. On the one hand, spreads on mezzanine and junior tranches continued to rise, with coupon rates on recently issued transactions nearing 10%; a result of more financial pressure on high-yield corporate issuers. On the other hand, AAA spreads stabilised at around 100bp, as tranches were generally unaffected by the lower collateral quality and benefited from strong investor demand.


Figure 2: Evolution of EUR CLO primary spreads



Source: Scope Ratings

As we noted in a previous research report ("Tight arbitrage spread leaves investors and European CLO managers with tougher decisions" – May 2019), spread arbitrage continues to be under pressure and is at its lowest level since the financial crisis. CLO managers are increasingly challenged when structuring new transactions and may have to accept lower equity returns as deal leverage is not being increased.

Figure 3: Evolution of EUR CLO spread arbitrage



Source: Scope Ratings

8 January 2020 2/5




Supply-demand mismatch

Leveraged loans: dry supply and lower credit quality

In Europe, investor appetite for leveraged loans was robust throughout 2019, aided by record-low default rates among high-yield issuers. Demand was led by banks and notably by CLOs, as the pace of new CLO issues accelerated in 2019. However, supply still fell short of demand: 2019 was the first year since 2013 where both primary and secondary activity decreased year-on-year.

The lack of jumbo deals was a key reason for the decline in leveraged loan issuance. This is closely linked to M&A activity, which fell 25% year-on-year in Europe in 2019, according to preliminary data from Refinitiv. Corporates have been particularly cautious, fearing threats of recession and ongoing uncertainties about Brexit, while facing continuous pressure on their operating performance. Cash holdings for both corporations and funds have increased as a result and could be used in financing leveraged buyouts if markets become more stable in 2020. This could help improve the net supply of leveraged loans, which recovered in the last few months of 2019 following more opportunistic deals across Europe.

Figure 4: EUR leveraged loans and M&A issuance



Source: Scope Ratings, Bloomberg

Deteriorating credit quality

The credit quality of the broader leveraged loans universe has worsened, however. Loans trading at below a EUR 80 cash price now account for 4.5%¹ of all European leveraged loans, the highest level since 2016. Additionally, issuers have seen their financial leverage increase, with the share of underlying debt-to-EBITDA ratios of above 6x now exceeding 35% of the outstanding universe, compared to c. 20% in 2015². The main contributors were healthcare and telecommunications companies, two sectors with a prevalence of buyouts and acquisitions, accounting for around 40% of leveraged loan volumes in Europe. Pharmaceuticals (e.g. Zentiva) and cable operators (e.g. Ziggo, Altice) show particularly high leverage.

8 January 2020 3/5

¹ Morgan Stanley (November 2019)

² BIS (September 2019)




The relatively high share of B- loans in the European universe will remain a threat for CLOs, as potential downgrades to CCC expose structures to market risk. A persistence in these difficult conditions could prompt some dislocation in manager performance. Decreasing credit quality has been accompanied by deteriorating underwriting standards at the lending level, with an increased share of cov-lite issuance. Moreover, weaker fundamentals have not been compensated for by higher premiums, as leveraged loan spreads remain within the 300bp-450bp range, similar to in 2018.

Adverse consequences on CLOs

For CLO managers and investors, these dynamics have three over-riding adverse effects: i) a significant overlap in loan collateral; ii) tight spread arbitrage; and iii) decreasing collateral quality, shown in the sharp rise in the average pool rating factor in the past few quarters.

Figure 5: Evolution of average pool rating factor³



Source: Scope Ratings

8 January 2020 4/5

³ As measured using Moody's WARF metric and data



Scope Ratings GmbH

Headquarters Berlin

Lennéstraße 5 D-10785 Berlin

Phone +49 30 27891 0

London

Suite 301 2 Angel Square London EC1V 1NY

Phone +44 20 3457 0444

Oslo

Haakon VII's gate 6 N-0161 Oslo

Phone +47 21 62 31 42

info@scoperatings.com www.scoperatings.com

Frankfurt am Main

Neue Mainzer Straße 66-68 D-60311 Frankfurt am Main

Phone +49 69 66 77 389 0

Madrid

Paseo de la Castellana 95 Edificio Torre Europa E-28046 Madrid

Phone +34 914 186 973

Paris

1 Cour du Havre F-75008 Paris

Phone +33 1 8288 5557

Milan

Via Paleocapa 7 IT-20121 Milan

Phone +39 02 30315 814

Disclaimer

© 2020 Scope SE & Co. KGaA and all its subsidiaries including Scope Ratings GmbH, Scope Analysis GmbH, Scope Investor Services GmbH and Scope Risk Solutions GmbH (collectively, Scope). All rights reserved. The information and data supporting Scope's ratings, rating reports, rating opinions and related research and credit opinions originate from sources Scope considers to be reliable and accurate. Scope does not, however, independently verify the reliability and accuracy of the information and data. Scope's ratings, rating reports, rating opinions, or related research and credit opinions are provided 'as is' without any representation or warranty of any kind. In no circumstance shall Scope or its directors, officers, employees and other representatives be liable to any party for any direct, indirect, incidental or other damages, expenses of any kind, or losses arising from any use of Scope's ratings, rating reports, rating opinions, related research or credit opinions. Ratings and other related credit opinions issued by Scope are, and have to be viewed by any party as, opinions on relative credit risk and not a statement of fact or recommendation to purchase, hold or sell securities. Past performance does not necessarily predict future results. Any report issued by Scope is not a prospectus or similar document related to a debt security or issuing entity. Scope issues credit ratings and related research and opinions with the understanding and expectation that parties using them will assess independently the suitability of each security for investment or transaction purposes. Scope's credit ratings address relative credit risk, they do not address other risks such as market, liquidity, legal, or volatility. The information and data included herein is protected by copyright and other laws. To reproduce, transfer, disseminate, translate, resell, or store for subsequent use for any such purpose the information and data contained herein, contact Scope Ratings GmbH at Lennéstraße 5 D-10785 Berlin.

Scope Ratings GmbH, Lennéstraße 5, 10785 Berlin, District Court for Berlin (Charlottenburg) HRB 192993 B, Managing Director: Guillaume Jolivet.

8 January 2020 5/5